Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
JAK inhibitors
Pharma
Incyte, Syndax bag FDA nod for potential GvHD blockbuster
Leerink Partners analysts have put Niktimvo’s peak sales at about $1 billion based on the drug’s potential to reach earlier lines of therapy.
Angus Liu
Aug 14, 2024 5:15pm
Incyte finds fun in pharma ad fatigue in Opzelura TV spot
Aug 6, 2024 6:45am
Leo Pharma builds its case for JAK inhibitor cream delgocitinib
Jan 24, 2024 10:36am
Incyte defends Jakafi against competitor drugs, patent cliff
Oct 31, 2023 11:23am
Galapagos sells its Jyseleca business to Italy's Alfasigma
Oct 31, 2023 9:10am
FDA approves GSK's Jakafi challenger in blood cancer
Sep 15, 2023 4:16pm
